NCT03340181 is a NA clinical trial of RIPC in OPCABG, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT03340181?

NCT03340181 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03340181?

Interventions in NCT03340181: RIPC.

Is NCT03340181 still recruiting?

NCT03340181 is currently status unknown. Last updated 13 November 2017.

Last reviewed 2017-11-13 · How we verify

NCT03340181

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Myocardial Protective Effect of Upper Limb Ischemic Preconditioning in Patients Undergoing Off-pump Coronary Artery Bypass Grafting

Status unknown NA Last updated 13 November 2017

What this trial tests

NA trial testing RIPC in OPCABG in 66 participants. Status unknown.

Timeline

1 November 2017

Primary endpoint
31 March 2019

30 June 2019

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	66
Start date	1 November 2017
Primary completion	31 March 2019
Estimated completion	30 June 2019
Sites	1 location across China

Drugs / interventions tested

RIPC

Conditions studied

OPCABG — all drugs for OPCABG →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 80, any sex, with OPCABG. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study was to verify the myocardial protective effect of RIPC in patients undergoing OPCABG.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response.
Pearce L, Davidson SM, Yellon DM. · · 2021 · cited 53× · PMID 33629195 · DOI 10.1007/s00395-021-00852-0
Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection.
Billah M, Ridiandries A, Allahwala U, Mudaliar H, et al · · 2019 · cited 37× · PMID 30719216 · DOI 10.18632/oncotarget.26537
Effects of Remote Ischemic Preconditioning in Patients Undergoing Off-Pump Coronary Artery Bypass Graft Surgery.
Wang H, Lyu Y, Liao Q, Jin L, et al · · 2019 · cited 17× · PMID 31110480 · DOI 10.3389/fphys.2019.00495

Verify or expand the search:

Other trials of RIPC

Trials testing the same drug.

NCT07181356 — Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction · NA · recruiting
NCT04766749 — Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon · NA · completed
NCT04433468 — Study on the Protective Effect of RIPC in Patients Undergoing Cardiac Surgery. · NA · completed
NCT03236441 — Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury · NA · completed
NCT04016857 — Remote Ischemic Preconditioning During Lower Limb Revascularization · NA · completed

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03340181 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 13 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03340181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing